Sign In
Buy CODX
$5.17
-1.05 (-16.88%)
At Close: Jun 03, 2026
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
09:00am, Monday, 03'rd Nov 2025
Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx's existing and future AI initiatives SALT LAKE CITY , Nov. 3, 2025 /PRNewswire
Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast
09:00am, Friday, 31'st Oct 2025
SALT LAKE CITY , Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests
SALT LAKE CITY , Oct. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
12:51pm, Wednesday, 29'th Oct 2025
SALT LAKE CITY , Oct. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
SALT LAKE CITY , Oct. 28, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia
08:30am, Wednesday, 22'nd Oct 2025
Conference attendance follows recent MOU announcement for a joint venture with a regional manufacturing and distribution company in the Kingdom of Saudi Arabia SALT LAKE CITY , Oct. 22, 2025 /PRNewswi
Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing
09:30am, Thursday, 16'th Oct 2025
New device has the potential to help empower decentralized PCR testing in nearly 30,000 primary health centers across India, advancing efforts to improve availability of life-saving TB diagnostics SAL
Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit
09:30am, Monday, 13'th Oct 2025
SALT LAKE CITY , Oct. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30
09:30am, Tuesday, 30'th Sep 2025
SALT LAKE CITY , Sept. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
SALT LAKE CITY , Sept. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development
Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
09:47am, Wednesday, 17'th Sep 2025
SALT LAKE CITY , Sept. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development
Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains
09:30am, Thursday, 11'th Sep 2025
SALT LAKE CITY , Sept. 11, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit
09:30am, Tuesday, 09'th Sep 2025
SALT LAKE CITY , Sept. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.
09:30am, Monday, 18'th Aug 2025
SALT LAKE CITY , Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript
07:42pm, Thursday, 14'th Aug 2025
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2025 Earnings Conference August 14, 2025 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Brian L. Brown - CFO & Company Secretary Dwig
